Breakthrough Research by Pulse Biosciences
Pulse Biosciences, Inc. (Nasdaq: PLSE) has recently made significant strides in cardiac surgery with the publication of a preclinical study in the Journal of Thoracic and Cardiovascular Surgery. This research highlights the innovative use of their Nanosecond Pulsed Field Ablation™ (nano-PFA) technology, which is showing promising results in the ablation of cardiac tissue.
Understanding Nano-PFA Technology
The study aimed to establish the safety and effectiveness of the innovative nano-PFA Cardiac Surgical System during cardiac surgeries. Conducted on porcine models, the procedures involved ablating various locations within all four heart chambers. By applying a sequence of short-duration electrical pulses over just 1.25 seconds, the technique proved effective, regardless of the tissue type or thickness. The encouraging outcomes validated the clinical advantages expected from the nano-PFA technology, with all lesions leading to consistent pulmonary veins exit blocks, a key indicator of effectiveness.
Expert Insights and Implications
Dr. Gan Dunnington, the Chief Medical Officer of Cardiac Surgery at Pulse Biosciences, expressed pride in the publication, noting, “The results of this study are extremely compelling because they demonstrate the potential for nano-PFA to consistently deliver contiguous and transmural ablations. Surgeons prioritize results that ensure positive outcomes, and this technology provides that capability.”
Dr. Niv Ad, the Chief Science Officer, added, “The non-thermal mechanism of action from nano-PFA signifies a paradigm shift in cardiac ablation. Our research aims to refine the treatment of atrial fibrillation, and we are grateful for the collaboration with surgeons who endorse our work.”
Cardiac Surgery System Specifications
The proprietary Cardiac Surgery System from Pulse is crafted to yield continuous, durable ablation lesions in the heart, specifically targeting atrial fibrillation. The innovation lies in its surgical clamp, which employs nanosecond PFA technology. According to pre-clinical findings, a single application lasting less than two seconds can achieve effective ablations significantly faster—about one-twentieth of the time compared to existing thermal ablation methods. Moreover, the absence of thermal spread minimizes risks of harming surrounding tissues, setting this technology apart from traditional radiofrequency techniques.
Future Steps and Commitment to Innovation
Pulse Biosciences is currently conducting a first-in-human feasibility study for atrial fibrillation at multiple centers, including three sites in Europe. The company is optimistic and anticipates sharing preliminary results of this important trial in the near future.
About Pulse Biosciences
Pulse Biosciences is dedicated to advancing bioelectric medicine. Their CellFX® nsPFA™ technology represents a novel approach, delivering rapid pulses of energy that can effectively clear cells while preserving adjacent non-cellular tissue. The ongoing development of this technology targets various fields, especially focusing on atrial fibrillation treatment. Based in Miami, Pulse Biosciences operates an additional office in Hayward, California.
Frequently Asked Questions
What is nano-PFA technology?
Nano-PFA technology involves delivering high-amplitude energy pulses to ablate cardiac tissue without causing thermal damage to surrounding areas.
How does Pulse Biosciences’ technology differ from traditional methods?
This technology is faster and minimizes the risk of collateral damage, providing consistent and effective ablation results compared to standard thermal ablation techniques.
What were the results from the preclinical study?
The study demonstrated that the nano-PFA system consistently produces effective ablations without injury to adjacent tissues, validating its clinical benefits.
What future studies is Pulse Biosciences undertaking?
They are currently conducting a multi-center feasibility study for atrial fibrillation and expect to share preliminary results soon.
Where is Pulse Biosciences headquartered?
Pulse Biosciences is headquartered in Miami, Florida, with additional operations in Hayward, California.
